PHARMACY

Laurry Hinds joins BioPlus

BY Allison Cerra

ALTAMONTE SPRINGS, Fla. — Laurry Hinds has been named regional director at BioPlus Specialty Pharmacy, responsible for business development in western North Carolina, the company announced.

Hinds, a registered nurse, will focus on hepatitis C and intravenous immunoglobulin sales. IVIG is a blood product used to treat certain immune deficiencies, autoimmune diseases and acute infections.

“We are delighted that Laurry has joined our business development team. She brings a rare combination of enthusiasm and knowledge that I know will create strong relationships with the referral sources in her market,” BioPlus VP sales Bill Cook said.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Galderma Labs launches new pump design for rosacea drug

BY Alaric DeArment

FORT WORTH, Texas — Galderma Labs has launched a newly designed pump dispenser for a drug used to treat rosacea, the drug maker said Tuesday.

Galderma announced the availability of the dispenser for MetroGel (metronidazole) gel in the 1% strength. The drug is used to treat bumps and blemishes in patients with rosacea. The Food and Drug Administration approved the pump in October.

"MetroGel 1% is the most widely prescribed branded topical medication for rosacea by physicians, and it makes sense to provide this proven treatment to patients in a way that suits their desire for more convenience," University of California Los Angeles clinical instructor of dermatology Debra Luftman said. "Not only will the pump make it simpler for patients to use the treatment, it may help provide consistent dosing so that patients use the correct amount of medication."

Rosacea, which is treatable but has no cure, affects more than 16 million people in the United States.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Taro committee continues to evaluate Sun offer, Taro says

BY Alaric DeArment

HAIFA BAY, Israel — A committee formed by Taro Pharmaceutical Industries in December is continuing to evaluate an acquisition offer by India-based Sun Pharmaceutical Industries, Taro said.

Sun is hoping to acquire Israel-based Taro for $24.50 per share.

The committee, comprising members of the company’s board of directors, has brought on Citigroup Global Markets as its financial adviser and is receiving legal advice from Israeli legal firm Goldfarb Seligman & Co. and U.S. firm Willkie Farr & Gallagher.

Sun originally sought to buy Taro in May 2007 for $7.75 per share, and both companies agreed to merge, but Taro terminated the merger agreement in May 2008. Sun has continued trying to acquire Taro since then.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES